T cell activation—the process by which these key immune defenders recognize threats and mobilize against them—depends on ...
CD8 + cytotoxic T lymphocytes (CTLs) serve as central effectors in cancer immunotherapy by directly eliminating tumor cells. However, current clinical therapies face significant limitations. These ...
A new immunotherapy drug has demonstrated early promise in a recent prostate cancer clinical trial. The drug, called VIR-5500 ...
T cells are the immune system’s frontline fighters. When they detect danger, they rapidly multiply and transform into effector cells that destroy pathogens. This transformation demands an intense ...
Durable reprogramming of human T cells may now be possible thanks to a new technique based on the CRISPRoff and CRISPRon methodology. Researchers from the Arc Institute, Gladstone Institutes, and the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results